Revisiting the role of molecular targeted therapies in patients with brain metastases

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Brain metastases (BM) present a significant challenge in cancer care, with surgical resection feasible only for a small patient subset.
• Current treatments like radiotherapy offer limited long-term local control, and conventional chemotherapies show poor efficacy due to the blood-brain barrier.
• There is a critical need for effective treatments for patients with unresectable BM.

Purpose of the Study:

• To review current data on targeted therapies approved for malignant tumors.
• To discuss the evidence supporting the use of these targeted therapies in patients with brain metastases.
• To highlight the potential of novel treatments for unresectable BM.

Main Methods:

• Literature review of approved targeted therapies.
• Analysis of clinical data on the efficacy of targeted agents in metastatic disease.
• Discussion of evidence for targeted therapy use specifically in brain metastases.

Main Results:

• Several targeted therapies (bevacizumab, erlotinib, gefitinib, sunitinib, sorafenib) are licensed and have shown improved survival in metastatic disease.
• These agents represent a promising avenue for managing brain metastases.
• Further investigation into their specific role and efficacy in unresectable BM is warranted.

Conclusions:

• Targeted therapies demonstrate potential for improving survival in patients with brain metastases.
• Their ability to overcome limitations of conventional treatments warrants further clinical evaluation for unresectable BM.
• This review consolidates current evidence on approved targeted therapies for brain metastases management.